➤ First patients dosed in Phase 3 program evaluating sustained drug delivery for DME ➤ FDA accepts supplemental NDA for presbyopia treatment ➤ FDA grants IND to ocular inflammation, pain treatment for potential expanded indication ➤ Enrollment complete in Phase 3 trial evaluating retinitis pigmentosa therapy ➤ ASCRS news and events
➤ Positive results in Phase 1 trial for geographic atrophy cell-based therapy ➤ Enrollment complete for Phase 3 DME drop trials ➤ Enrollment complete in study for hydrogel retinal sealant ➤ First patient dosed in Phase 2 trial studying oral diabetic retinopathy therapy ➤ Regenerative Medicine Advanced Therapy designation granted to gene therapy candidate for X-linked retinoschisis ➤ ASCRS news and events
➤ FDA approves IND for neuropathic pain drug ➤ Phase 2 preliminary efficacy and safety data for wet AMD treatment trial ➤ First-in-human data for DME, AMD therapy ➤ Study: Rapid eye stroke detection protocol helps prevent vision loss ➤ Enrollment complete for Phase 3 trial for sozinibercept ➤ ASCRS news and events
➤ Study evaluates safety of office-based lens surgery ➤ FDA issues response to BLA for 8 mg aflibercept ➤ Pre-clinical data for non-viral gene therapy ➤ Non-human primate study of dry AMD therapy ➤ Expanded insurance coverage for MIGS procedures ➤ ASCRS news and events
➤ Topline results from Phase 3 study of atropine for myopia progression ➤ Phase 3 results for novel glaucoma drop ➤ Positive results from two Phase 3 studies for patients with RVO ➤ Phase 3 results for cell therapy treating macular telangiectasia type 2 ➤ Single injection of investigational compound for DME improves BCVA ➤ FDA accepts BLA for ophthalmic bevacizumab ➤ Mobile phone attachment developed for ophthalmic clinical trials ➤ ASCRS news and events
➤ Small-aperture IOL receives FDA approval ➤ First patient enrolled in new LASIK trial ➤ Safety of sustained-release intravitreal implant confirmed ➤ Dosing complete in Phase 1/2a trial for injectable wet AMD therapy ➤ First patient dosed in light-activated optogenetic monotherapy study ➤ Phase 2 study for investigational new immunomodulator to treat dry eye disease ➤ Partnership created to develop tissue implant therapies ➤ ASCRS news and events
➤ FDA approves brolucizumab injection for DME ➤ NDA filed for geographic atrophy drug ➤ Study: Dietary supplements can slow AMD progression ➤ First global study evaluates AI for diabetic retinopathy and referral uptake ➤ Plans to begin two Phase 3 trials for investigational thyroid eye disease therapy ➤ ASCRS news and events
➤ Topline data from Phase 3 trial of presbyopia-correcting drop ➤ FDA gives 510(K) approval to updated neuromodulation therapy for increased tear production ➤ Enrollment complete for Phase 3 trial of reproxalap ➤ DME trial to focus on underrepresented patient populations ➤ BLA submitted to FDA for wet AMD therapy ➤ Companies collaborate to further develop gene therapy for retinal disease ➤ ASCRS news and events
➤ Study: Possible therapy to avoid visual problems induced by space travel ➤ Exploratory study finds investigational eye drop for dry eye safe and tolerable ➤ New drug candidate in development to treat dry eye and ocular pain ➤ Results from year 2 of Phase 3 trial of brolucizumab for DME ➤ ASCRS news and events